GlassScriptPhysician profile
Gargi Patel
NPI 1417355959
$1,854.45
in general payments reported to CMS, 2019-2025
10 companies · $776 in 2025
The $776 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.08 · 2020: $101 · 2021: $214 · 2022: $203 · 2023: $15.47 · 2024: $511 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.12 |
| Education | $164.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $472.11 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $466.57 | 2021-2025 | Dupixent |
| Csl Behring | $287.83 | 2021-2025 | Haegarda, Andembry |
| Amgen INC. | $171.72 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $140.94 | 2022-2024 | |
| Optinose US, INC. | $117.58 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.81 | 2020-2021 | |
| Pharming Healthcare, INC. | $19.00 | 2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gargi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.